Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00835)
Name
Amisulpride
Synonyms    Click to Show/Hide the Synonyms of This API
amisulpride; 71675-85-9; Solian; Aminosultopride; Deniban; Amisulprida; DAN 2163; Amisulpridum; DAN-2163; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; C17H27N3O4S; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; Amisulpride free base; APD421; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide; 4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide; CHEBI:64045; 71675-85-9 (free base); MFCD00866691; NCGC00092310-03; DSSTox_CID_22613; DSSTox_RID_80058; DSSTox_GSID_42613; Amisulpridum [INN-Latin]; Amisulprida [INN-Spanish]; Amisulpiride; Sulpitac; Socian; 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-ethylsulfonyl-2-methoxybenzamide; SMR000449309; Deniban (TN); Amisulpride (INN); CAS-71675-85-9; Solian (TN); Amisulpride [INN:BAN]; EINECS 275-831-7; Barhemsys; Amisulpride/; Amisulpride-d5; Barhemsys (TN); 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-anisamid; (plusmn)-amisulpride; 1216626-17-3; PubChem18224; SL-91.1077; SCHEMBL34126; GTPL963; MLS000758258; MLS000759450; MLS001424039; MLS006011769; CHEMBL243712; DTXSID5042613; Amisulpride, >=98% (HPLC); BDBM81790; APD-421; BCPP000404; HMS2051K10; HMS2235M16; HMS3263D07; HMS3268L09; HMS3369K09; HMS3393K10; HMS3413G07; HMS3657E11; HMS3677G07; HMS3713N06; HMS3884A09; Pharmakon1600-01502285; BCP02089; NSC_2159; Tox21_113392; Tox21_501133; ABP000597; ANW-42197; CA0133; NSC760085; STK635172; STL454297; AKOS005567252; Tox21_113392_1; AC-6820; BCP9000294; CCG-100860; CCG-220622; CCG-222437; CS-1791; DB06288; LP01133; LS41262; MCULE-4239265090; NC00110; NSC-760085; SDCCGSBI-0633795.P001; 4-amino-5-(ethanesulfonyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide; NCGC00092310-01; NCGC00092310-02; NCGC00092310-04; NCGC00092310-06; NCGC00092310-16; NCGC00261818-01; AS-13890; HY-14545; K214; AB0008029; CAS_71675-85-9; AK00472461; FT-0630805; S1280; SW197490-3; D07310; AB00639933-07; AB00639933-09; AB00639933_10; 675A859; A837282; L000106; Q418785; SR-01000759303; SR-01000759303-5; W-104511; BRD-A60197193-001-05-4; Amisulpride, British Pharmacopoeia (BP) Reference Standard; Amisulpride, European Pharmacopoeia (EP) Reference Standard; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl) methyl]-5-(ethylsulfonyl)-2-benzamide; 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-benzamide; 4-amino-5-ethanesulfonyl-n-(1-ethyl-pyrrolidin-2-ylmethyl)-2-methoxy-benzamide; 4-Amino-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)- 2-methoxybenzamide; 4-azanyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide; Amisulpride for system suitability, European Pharmacopoeia (EP) Reference Standard; Benzamide,4-amino-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-5-(ethylsulfonyl)-2-methoxy-; 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-methoxybenzenecarboximidic acid
Clinical Status
Approved
PubChem CID
2159
Formula
C17H27N3O4S
Canonical SMILES
CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
InChI
1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
InChIKey
NTJOBXMMWNYJFB-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=2159"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 369.5 Topological Polar Surface Area 110
XlogP 1.5 Complexity 549
Heavy Atom Count 25 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Amisulpride 5mg/2ml solution Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Citric Acid Monohydrate; Sodium Chloride; Trisodium Citrate Dihydrate; Hydrochloric Acid Nf; Sodium Hydroxide Nf; Water For Injection
                   Dosage Form Solution
                   Company Acacia
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hydrochloric acid DIG Info Carbonic anhydrase V (Ki = 156 nM) [1]
          Amisulpride 10mg/4ml solution Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Citric Acid Monohydrate; Sodium Chloride; Trisodium Citrate Dihydrate; Hydrochloric Acid Nf; Sodium Hydroxide Nf; Water For Injection
                   Dosage Form Solution
                   Company Acacia
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hydrochloric acid DIG Info Carbonic anhydrase V (Ki = 156 nM) [1]
References
1 Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1; 14(21):5435-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.